Gilead Offers Its Newest Hiv Drug Candidate To Patent Pool For Low-Cost Production
Gilead Sciences Is Licensing Its Newest Hiv Drug Candidate, Bictegravir, To The U.N.-Backed Medicines Patent Pool, Meaning It Will Be Produced And Sold At A Lower Cost In 116 Low- And Middle-Income Countries Once It Is Approved.Gilead Said It Will Include The Hiv-1 Candidate In Its Existing Agreements With Generic Drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan And Sequent Scientific, As A Single Agent Or In Fixed-Dose Combinations With Other Hiv Medicines,
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
